版本:
中国

BRIEF-Aptevo Therapeutics anticipated experiencing supply interruption of Ixinity 1,500 IU dosage form beginning Dec 2016 - SEC filing

Nov 28 Aptevo Therapeutics Inc

* Aptevo Therapeutics says on Nov 14, reported co anticipated experiencing supply interruption of Ixinity 1,500 IU dosage form beginning Dec 2016 - SEC filing

* Aptevo Therapeutics says anticipated experiencing supply interruption of Ixinity's all other dosage forms beginning Jan 2017 - SEC filing

* Aptevo Therapeutics says supply interruption relates to challenges associated with manufacture of bulk drug substance (BDS) for ixinity

* Aptevo Therapeutics says continuing to work with BDS supplier to resolve ixinity manufacturing issue Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐